Breaking News

Financial Report: AMRI

By Kristin Brooks | February 12, 2014

Achieves record contract revenues

AMRI
 
4Q Revenues: $67.1 million (flat)

4Q Earnings: $4.5 million (+137%)

FY Revenues: $246.6 million (+9%)

FY Earnings: $12.7 million (loss of $3.8 million FY12)

Comments: Contract revenue for the quarter was a record $59.7 million, up 1%. Royalty revenue in the quarter was $7.4 million, down 9%, and includes royalties from the Allegra products as well as $2.3 million from sales of certain amphetamine salts sold by Actavis. Contract revenue for the year was a record $210.0 million, up 11%, while royalty revenue was $36.6 million, up 2%. Discovery Services and Development / Small Scale Manufacturing (DDS) contract revenue for the quarter was $18.4 million, down 12%, with lower revenue in Development / Small Scale Manufacturing, partially offset by higher Discovery Services revenue, and for the year was $77.4 million, up 5%. Large Scale Manufacturing revenue for the quarter was $41.3 million, up 8%, and $132.6 million for the year, up 14%.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016